A Study on Enhancing Pancreatic Islet Function in Type 2 Diabetes and Coronary Heart Disease Patients with Liraglutide and Metformin Combination Therapy

Proceedings of Anticancer Research Pub Date : 2023-11-22 DOI:10.26689/par.v7i6.5566

Chunxiao Yang

{"title":"A Study on Enhancing Pancreatic Islet Function in Type 2 Diabetes and Coronary Heart Disease Patients with Liraglutide and Metformin Combination Therapy","authors":"Chunxiao Yang","doi":"10.26689/par.v7i6.5566","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the impact of combining liraglutide with metformin on the enhancement of pancreatic islet function in patients with type 2 diabetes and coronary heart disease. Methods: 60 patients with type 2 diabetes and coronary heart disease admitted from February 2022 to August 2023 were selected as research subjects. They were randomly assigned to either control or treatment groups, with 30 patients in each. The control group received metformin alone, while the treatment group received liraglutide in combination with metformin. Various indicators, including blood sugar levels, pancreatic islet function, and cardiac function between the two groups were compared. Results: The results of FPG, 2hPG, HbA1c, HOMA-IR, NT-proBNP, and LVEDD in the treatment group were lower than those in the control group, whereas the values of FINS, HOMA-β, E/A, and LVEF in the treatment group were higher than those in the control group (P < 0.05). Conclusion: The use of liraglutide in combination with metformin significantly benefits patients with type 2 diabetes and coronary heart disease. It leads to improved pancreatic islet function, better blood sugar control, and enhanced cardiac function. This combination therapy is recommended for clinical adoption.","PeriodicalId":20511,"journal":{"name":"Proceedings of Anticancer Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of Anticancer Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26689/par.v7i6.5566","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the impact of combining liraglutide with metformin on the enhancement of pancreatic islet function in patients with type 2 diabetes and coronary heart disease. Methods: 60 patients with type 2 diabetes and coronary heart disease admitted from February 2022 to August 2023 were selected as research subjects. They were randomly assigned to either control or treatment groups, with 30 patients in each. The control group received metformin alone, while the treatment group received liraglutide in combination with metformin. Various indicators, including blood sugar levels, pancreatic islet function, and cardiac function between the two groups were compared. Results: The results of FPG, 2hPG, HbA1c, HOMA-IR, NT-proBNP, and LVEDD in the treatment group were lower than those in the control group, whereas the values of FINS, HOMA-β, E/A, and LVEF in the treatment group were higher than those in the control group (P < 0.05). Conclusion: The use of liraglutide in combination with metformin significantly benefits patients with type 2 diabetes and coronary heart disease. It leads to improved pancreatic islet function, better blood sugar control, and enhanced cardiac function. This combination therapy is recommended for clinical adoption.

查看原文本刊更多论文

利拉鲁肽和二甲双胍联合疗法增强 2 型糖尿病和冠心病患者胰岛功能的研究

目的探讨利拉鲁肽与二甲双胍联合应用对增强2型糖尿病合并冠心病患者胰岛功能的影响。方法：选取 2022 年 2 月至 2023 年 8 月期间收治的 60 例 2 型糖尿病合并冠心病患者作为研究对象。他们被随机分配到对照组或治疗组，每组 30 人。对照组单独服用二甲双胍，治疗组在服用二甲双胍的同时服用利拉鲁肽。对两组患者的血糖水平、胰岛功能和心脏功能等各项指标进行比较。结果治疗组的FPG、2hPG、HbA1c、HOMA-IR、NT-proBNP和LVEDD结果低于对照组，而治疗组的FINS、HOMA-β、E/A和LVEF值高于对照组（P＜0.05）。结论利拉鲁肽与二甲双胍联用可显著改善2型糖尿病合并冠心病患者的病情。它能改善胰岛功能，更好地控制血糖，增强心脏功能。建议临床采用这种联合疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Proceedings of Anticancer Research

自引率

0.00%

发文量